NCT05447078

Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection

Impact of Oral Immulina TM on Natural Killer Cell Activities and Other Biomarkers Associated With Increasing Host Immune Resilience to Upper Respiratory Viruses in Normal Human Volunteers

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 492 (actual)
• Sponsor: University of Mississippi Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, Immulina TM, on enhancing host resilience to the effects of viral influenza infection in humans.

Detailed description

This randomized, double blind, placebo controlled study aims to establish the impact of the oral supplement, Immulina TM, on increasing host resilience against the pathogenic effects of influenza virus infection in normal and immune compromised individuals by measuring a biomarker profile designed to reflect immune components associated with antiviral natural killer cell numbers and activity, cytotoxic T cell numbers, vaccine-related flu-specific antibody responses and cytokine profiles associated with host antiviral innate and adaptive immune responses.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	Immulina TM	Immulina TM is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
DIETARY_SUPPLEMENT	Placebo	Placebo is inert powder in cellulose capsule that appears identical to Immulina TM capsules.

Timeline

• Start date: 2022-07-01
• Primary completion: 2025-12-08
• Completion: 2025-12-08
• First posted: 2022-07-07
• Last updated: 2025-12-26

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study